<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295475</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-357</org_study_id>
    <nct_id>NCT02295475</nct_id>
  </id_info>
  <brief_title>Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome</brief_title>
  <acronym>ASTRO-APS</acronym>
  <official_title>Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASTRO-APS is a prospective, randomized, open-label blinded endpoint pilot study among
      patients with a clinical diagnosis of the AntiPhospholipid Syndrome and are already taking an
      anticoagulant for the secondary prevention of thrombosis (blood clots). Subjects will be
      randomized to receive either warfarin (target INR range 2-3) or apixaban 5 mg twice daily.
      Patients will follow up with the study team for 13 months. 2 in-clinic follow-up visits will
      be performed as well as 4 telephone follow-up visits. Study participants will be asked to
      consent to follow up telephone calls and questionnaires at 3 month intervals following the
      completion of the study procedures for the main portion of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study has two primary aims. The first is to identify patients with a clinical
      diagnosis of APS and then describe their recruitment, enrollment, screening failure rate,
      adherence to therapy, clinical characteristics, and APS diagnostic criteria in terms of
      broadly accepted published standards. Essential in this aim is capture of ability to
      identify, recruit, randomize, and retain patients with APS receiving a direct oral
      anticoagulant. We will also report compliance and patient satisfaction; central to durable
      anticoagulation management.

      The second aim is to report rates of thrombosis (arterial or venous) and death caused by
      thrombosis, as well as major bleeding plus clinically relevant non-major bleeding over one
      year among APS patients randomized to either warfarin or apixaban. As such, we will report
      the rate of Thrombosis (arterial and/or venous) [ Time Frame: Up to 13 months after
      enrollment ] [ Designated as safety issue: No ] and Major and non-major bleeding [ Time
      Frame: Up to 13 months after enrollment ] [ Designated as safety issue: Yes ]
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Thrombosis (arterial and/or venous)</measure>
    <time_frame>Up to 13 months after enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major and non-major bleeding</measure>
    <time_frame>Up to 13 months after enrollment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive warfarin for the duration of the study. The dose and how frequently warfarin is taken depends on the results of the patient's INR blood test(s). The target INR range for this study is 2-3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Study subjects will be randomized to receive Apixaban.</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Study subjects will be randomized to receive Warfarin.</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be ≥ 18 years of age

          2. Have a clinical diagnosis of the APS for which the patient is receiving
             anticoagulation therapy for the secondary prevention of thrombosis

        2.a. Anticoagulation is defined as warfarin sodium titrated at the discretion of the
        clinician to a target INR 2.5 (range 2-3), 3.0 (range 2.5-3.5), or 3.5 (range 3-4).

        2. b. Should the patient be receiving some other form of anticoagulation (apixaban,
        rivaroxaban, edoxaban, dabigatran etexilate, low-molecular weight heparin) and are willing
        to be randomized to warfarin with a target INR 2.5 or apixaban 5 mg PO BID and they meet
        all other inclusion criteria

        3. Have completed at least 6months of anticoagulation for the indication of thrombosis and
        are without acute neurologic symptoms consistent with thrombosis, CVA, or TIA for a minimum
        of six months.

        4. Be willing to provide informed consent to contact the subjects anticoagulation provider
        for INRs and dosing as well as details regarding any adverse events

        5. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
        test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
        start of study drug.

        6. Women must not be breastfeeding

        7. Women of childbearing potential must agree to follow instructions for method(s) of
        contraception for the duration of treatment with study drug apixaban plus 5 half-lives of
        study drug apixaban (3 days) plus 30 days (duration of ovulatory cycle) for a total of 33
        days post-treatment completion.

        8. Males who are sexually active with women of childbearing potential must agree to follow
        instructions for method(s) of contraception for the duration of treatment with study drug
        apixaban plus 5 half-lives of the study drug apixaban (3 days) plus 90 days (duration of
        sperm turnover) for a total of 93 days post-treatment completion.

        9. Azoospermic males and women of childbearing potential who are continuously not
        heterosexually active are exempt from contraceptive requirements. However they must still
        undergo pregnancy testing.

        10. Be willing to undergo magnetic resonance imaging (MRI) of the brain

        Exclusion Criteria:

          1. Another indication for long-term anticoagulation for which no FDA approval of apixaban
             exists (e.g. mechanical heart valve)

          2. A life expectancy of less than 1 year

          3. Is unable to attend follow-up appointments

          4. Is participating in a conflicting clinical trial or has participated in a trial within
             the last 30 days

          5. Is receiving concomitant dual antiplatelet therapy

          6. Requires aspirin dose of greater than 165mg daily

          7. A hemoglobin level of less than 8 mg per deciliter

          8. A platelet count of less than 50,000 per cubic millimeter

          9. Serum creatinine level of more than 2.5 mg per deciliter (221 μmol per liter) or a
             calculated creatinine clearance of less than 25 ml per minute

         10. Alanine aminotransferase or aspartate aminotransferase level greater than 2 times the
             upper limit of the normal range

         11. A total bilirubin more than 1.5 times the upper limit of the normal range.

         12. Have active cancer for which treatment (chemotherapy/radiation therapy) is being
             delivered or has been delivered within the last 3 months

         13. Are actively receiving a strong dual inhibitor of CYP3A4 and P-gp, such as:

        13.a Ketoconazole 13.b Itraconazole 13.c Ritonavir 13.d clarithromycin

        14. Are actively taking a strong dual inducer of CYP3A4 and P-gp, such as: 14.a rifampin
        14.b carbamazepine 14.c phenytoin 14.d St. John's wort

        15. Intend pregnancy or breastfeeding within the next year

        16. Have a known allergy to apixaban, rivaroxaban, or edoxaban

        17. Have experienced thrombosis while receiving warfarin at a target INR of 2-3 and have
        been assigned a higher target INR at the discretion of their clinician.

        18. Patients with active pathological bleeding.

        19. A history of arterial thromboembolism (e.g., stroke, myocardial infarction or other
        arterial thrombosis)

        20. Requires clopidogrel, tigacrolor, prasugrel, or another P2Y12 inhibitor

        21. Have a history of catastrophic APS (CAPS) as defined by clinical routine

        22. Have radiographic evidence of prior arterial thrombosis on MRI as defined per clinical
        routine upon screening MRI

        23. At the discretion of the investigator are considered to not be candidates secondary to
        s a safety concern.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott C Woller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott C Woller, MD</last_name>
    <phone>801-507-3376</phone>
    <email>Scott.Woller@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Aston, BS</last_name>
    <phone>801-507-4606</phone>
    <email>Valerie.Aston@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauna Bruun</last_name>
      <phone>801-408-2137</phone>
      <email>Shauna.Bruun@imail.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306.</citation>
    <PMID>16420554</PMID>
  </reference>
  <reference>
    <citation>Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.</citation>
    <PMID>23216615</PMID>
  </reference>
  <reference>
    <citation>Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.</citation>
    <PMID>23808982</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.</citation>
    <PMID>21309657</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</citation>
    <PMID>21870978</PMID>
  </reference>
  <reference>
    <citation>Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes. 2012 Sep 26;10:120. doi: 10.1186/1477-7525-10-120.</citation>
    <PMID>23013426</PMID>
  </reference>
  <reference>
    <citation>Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost. 2013 Oct;110(4):732-41. doi: 10.1160/TH13-03-0243. Epub 2013 Jul 11.</citation>
    <PMID>23846019</PMID>
  </reference>
  <reference>
    <citation>Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010 Apr;19(4):486-91. doi: 10.1177/0961203310361355. Review.</citation>
    <PMID>20353992</PMID>
  </reference>
  <reference>
    <citation>Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992 Apr;21(5):275-86.</citation>
    <PMID>1604324</PMID>
  </reference>
  <reference>
    <citation>Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR. The &quot;primary&quot; antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore). 1989 Nov;68(6):366-74.</citation>
    <PMID>2509856</PMID>
  </reference>
  <reference>
    <citation>Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med. 1994 Jan;96(1):3-9.</citation>
    <PMID>8304360</PMID>
  </reference>
  <reference>
    <citation>Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015 Jun;74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838. Epub 2014 Jan 24.</citation>
    <PMID>24464962</PMID>
  </reference>
  <reference>
    <citation>Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003 Oct 15;102(8):2717-23. Epub 2003 Jun 19. Review.</citation>
    <PMID>12816875</PMID>
  </reference>
  <reference>
    <citation>Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29;117(4):e25-146. Epub 2007 Dec 17. Erratum in: Circulation. 2010 Jul 6;122(1):e10. Kissela, Bret [corrected to Kissela, Brett].</citation>
    <PMID>18086926</PMID>
  </reference>
  <reference>
    <citation>Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577.</citation>
    <PMID>13679527</PMID>
  </reference>
  <reference>
    <citation>Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25(4):191-3. Review.</citation>
    <PMID>8792794</PMID>
  </reference>
  <reference>
    <citation>Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005 May;127(5):1515-22.</citation>
    <PMID>15888822</PMID>
  </reference>
  <reference>
    <citation>van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006 May;129(5):1155-66. Review.</citation>
    <PMID>16685005</PMID>
  </reference>
  <reference>
    <citation>Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992 Aug;1(2):113-9.</citation>
    <PMID>1366259</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.</citation>
    <PMID>19717844</PMID>
  </reference>
  <reference>
    <citation>Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011 May;31(4):407-16. doi: 10.1007/s11239-011-0549-x.</citation>
    <PMID>21359646</PMID>
  </reference>
  <reference>
    <citation>EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.</citation>
    <PMID>22449293</PMID>
  </reference>
  <reference>
    <citation>Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.</citation>
    <PMID>18579812</PMID>
  </reference>
  <reference>
    <citation>Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992 Aug 15;117(4):303-8.</citation>
    <PMID>1637025</PMID>
  </reference>
  <reference>
    <citation>Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7.</citation>
    <PMID>7885428</PMID>
  </reference>
  <reference>
    <citation>Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med. 2002 May 27;162(10):1164-9.</citation>
    <PMID>12020188</PMID>
  </reference>
  <reference>
    <citation>Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Apr;157(1):47-58. doi: 10.1111/j.1365-2141.2012.09037.x. Epub 2012 Feb 8. Review.</citation>
    <PMID>22313321</PMID>
  </reference>
  <reference>
    <citation>Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood. 2009 Sep 3;114(10):2020-30. doi: 10.1182/blood-2009-05-220756. Epub 2009 Jul 8. Review.</citation>
    <PMID>19587374</PMID>
  </reference>
  <reference>
    <citation>Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost. 2012 Jun;38(4):339-47. doi: 10.1055/s-0032-1304720. Epub 2012 Mar 30. Review.</citation>
    <PMID>22467528</PMID>
  </reference>
  <reference>
    <citation>Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol. 2014 Jan;3(1):9-17. doi: 10.12860/jnp.2014.03. Epub 2014 Jan 1. Review.</citation>
    <PMID>24644537</PMID>
  </reference>
  <reference>
    <citation>Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993 Mar 1;69(3):236-9.</citation>
    <PMID>8470047</PMID>
  </reference>
  <reference>
    <citation>Cronan JJ. Venous thromboembolic disease: the role of US. Radiology. 1993 Mar;186(3):619-30. Review.</citation>
    <PMID>8430164</PMID>
  </reference>
  <reference>
    <citation>Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P, Noventa F, Benedetti L, Girolami A. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation. 1993 Oct;88(4 Pt 1):1730-5.</citation>
    <PMID>8403319</PMID>
  </reference>
  <reference>
    <citation>Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker SG, Makdissi R, Guyatt GH. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e351S-e418S. doi: 10.1378/chest.11-2299.</citation>
    <PMID>22315267</PMID>
  </reference>
  <reference>
    <citation>Stein PD, Gottschalk A, Sostman HD, Chenevert TL, Fowler SE, Goodman LR, Hales CA, Hull RD, Kanal E, Leeper KV Jr, Nadich DP, Sak DJ, Tapson VF, Wakefield TW, Weg JG, Woodard PK. Methods of Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III). Semin Nucl Med. 2008 Nov;38(6):462-70. doi: 10.1053/j.semnuclmed.2008.06.003. Review.</citation>
    <PMID>19331840</PMID>
  </reference>
  <reference>
    <citation>PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 1990 May 23-30;263(20):2753-9.</citation>
    <PMID>2332918</PMID>
  </reference>
  <reference>
    <citation>van Belle A, Büller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW, Kramer MH, Kruip MJ, Kwakkel-van Erp JM, Leebeek FW, Nijkeuter M, Prins MH, Sohne M, Tick LW; Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006 Jan 11;295(2):172-9.</citation>
    <PMID>16403929</PMID>
  </reference>
  <reference>
    <citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4.</citation>
    <PMID>15842354</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

